Cite
HARVARD Citation
Mease, P. et al. (n.d.). THU0325 Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses. Annals of the rheumatic diseases. pp. 381-382. [Online].